Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma

We designed a phase I/II trial of S-1 combined with weekly docetaxel to determine the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate the efficacy and toxicity in metastatic gastric carcinoma (MGC). Patients with measurable disease received S-1 orally b.i.d. on days 1–14 and d...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, S R, Kim, H K, Kim, C G, Choi, I J, Lee, J S, Lee, J H, Ryu, K W, Kim, Y-W, Bae, J-M, Kim, N K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361699/
https://www.ncbi.nlm.nih.gov/pubmed/18362939
http://dx.doi.org/10.1038/sj.bjc.6604312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361699/
https://www.ncbi.nlm.nih.gov/pubmed/18362939
http://dx.doi.org/10.1038/sj.bjc.6604312

Ejemplares similares